Accendra Health (ACH) delivered a third-quarter report that was less an earnings miss than a full reset. The company lost $0.23 per share from continuing operations against a consensus loss of $0.05, a 360.0% negative surprise, on revenue of $601.78 million that fell 3.4% short of the $623.1 million estimate. Adjusted earnings swung from a $0.25 profit a year ago to a $0.23 loss. GAAP and adjusted results were identical this quarter, which removes the usual cushion of non-GAAP add-backs. Management cut full-year guidance for the third time in 2026, and a new chief executive acknowledged that the business had "fallen well short" of expectations and lost market share. The central tension is simple: a turnaround plan now has to be executed under a balance sheet that leaves very little room for error.

The quality of the quarter does not improve on closer inspection. Revenue fell from $697.3 million a year ago, partly because of an exited commercial payer. The more telling figure is that revenue excluding that payer declined about 1%, the first year-over-year drop in 2026, after gains of 2% in the second quarter and 1% in the first. Adjusted EBITDA nearly halved to $47.8 million from $92.2 million and fell from $60 million in the second quarter. Cost of revenue rose 280 basis points to 56.6% of sales. SG&A climbed to 41.5% of revenue from 38.1% a year earlier. Operating income was just $1.3 million against $37.6 million of net interest expense. The GAAP loss would have been much deeper without an $18.9 million tax benefit. Even the modest $5.5 million exit-and-realignment line was flattered by a $33 million gain on a non-core asset sale.

The call explained why demand weakened. The new CEO said Accendra ceded share in sleep and respiratory even as those markets grew. He cited intake friction, low e-prescribe adoption, order rework, early attrition among sleep patients before they reach 90-day compliance, and weak resupply retention. These are operating failures within the company's control rather than market-wide headwinds. That makes them fixable in principle but damning for prior execution. The segment detail was broadly soft:

• Sleep still grew more than 4% excluding the exited payer, slowing from about 5.5% in the second quarter.
• Diabetes swung to a 3% decline from 4% growth.
• Respiratory fell 6.5% and wound care fell 6%.

The tone change was stark. Prior management had projected strong confidence, while the new team offered candor, a departing COO, and no timeline for the dollar impact of its initiatives.

Guidance now carries most of the weight. Revenue is expected at the bottom of the $2.45 billion to $2.55 billion range, down from an original $2.55 billion to $2.65 billion. Adjusted EBITDA could come in as much as 30% below the $310 million midpoint, or roughly $217 million, compared with $335 million to $355 million set in February. The second-quarter promise that the fourth quarter would be the year's strongest has been abandoned, with fourth-quarter EBITDA now expected roughly flat with the third. Free cash flow, originally targeted near $100 million, is pressured further. Third-quarter free cash flow of $5.8 million also benefited from interest paid falling to $10.9 million while accrued interest rose $29.4 million, a timing effect rather than a durable improvement.

The balance sheet is where bears have their strongest ammunition. Cash stood at $26.6 million and net debt at $1.73 billion, up $18 million sequentially. Measured against the guided EBITDA run-rate, that is very heavy leverage, and an analyst questioned liquidity directly on the call. Mitigating factors exist:

• Roughly $300 million of available liquidity.
• An accounts-receivable securitization extended to October 2029.
• A first debt maturity not due until early 2029.
• Payer prepayment audits largely resolved, with cash starting to flow.
• A targeted $14 million fourth-quarter asset sale.
• 2027 equipment capex expected to fall meaningfully, since 2026 spending included $35 million tied to the exited payer.

The release also references the company's ability to cure noncompliance with NYSE listing standards, a reminder of how far the equity has fallen.

The market had largely anticipated the damage. Shares closed at $0.28 before the report, down 84.2% from the $1.74 open after the August release and about 87.5% below the $2.20 200-day moving average. The stock hit a 52-week low of $0.19 on October 23 and entered earnings about 44% above that level. Investor sentiment deteriorated meaningfully, from -0.40 to -0.63. Momentum and AVWAP trend readings remain negative, consistent with a stock that has been liquidated rather than accumulated.

The bottom line is that Accendra's third quarter replaced a growth narrative with a turnaround narrative. Revenue excluding the exited payer is shrinking, margins are compressing on both gross and SG&A lines, and guidance has been cut three times in nine months. The new CEO's candor and the promised early-2027 plan are the only real catalysts, but they arrive without quantified targets and against roughly $1.73 billion of net debt. With the share price already near record lows, the equity has become an option on execution, and this report gave investors little reason yet to believe that execution will come quickly.